Substantia Nigra Dopamine In Corticobasal Degeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Corticobasal Degeneration (CBD) is a tauopathy that affects the Substantia Nigra pars compacta (SNc), leading to parkinsonian features. The pattern of dopaminergic loss differs from Parkinson's disease.
| Property | Value |
|---|---|
| Category | Dopaminergic Nucleus in Tauopathy |
| Location | Midbrain, substantia nigra |
| Cell Types | Dopaminergic neurons (A9) |
| Neurotransmitter | Dopamine |
| Key Markers | TH, DAT, tau pathology |
The study of Substantia Nigra Dopamine In Corticobasal Degeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Armstrong MJ, et al. Corticobasal degeneration. Lancet Neurol. 2021;20(12):958-968.
[2] Dickson DW, et al. Neuropathology of CBD. Acta Neuropathol. 2020;139(5):733-746.
[3] Litvan I, et al. Clinical features of CBD. Mov Disord. 2019;34(4):476-486.